Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Pathophysiology and Treatment of Fibromyalgia Syndrome

Author(s): Thomas Stratz, Marion Schneider, Thomas O. Joos, Hsin-Yun Hsu and Wolfgang Muller

Volume 3 , Issue 2 , 2007

Page: [167 - 170] Pages: 4

DOI: 10.2174/157339707780619386

Price: $65

Abstract

Fibromyalgia syndrome is not a diagnosis in itself, but merely represents a set of classification criteria. It is possible to distinguish between different subgroups. Such a distinction can be made on the basis of psychopathological, clinical and laboratory tests. One subgroup reveals elevated level of different cytokines. The treatment of primary fibromyalgia can be optimized by taking these subgroups into consideration since one group responds better to 5-HT3 receptor antagonists, whereas another benefits more from antidepressants and a third group from psychotherapy. In socalled secondary fibromyalgia, 5-HT3 receptor antagonists may be used in the attempt to manage pain that might still persist after treatment of the primary disease.

Keywords: Fibromyalgia, subgroups, antidepressants, treatment, tropisetron, 5-HT3-receptor antagonists, psychotherapy


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy